Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 7, 2013, Pages 1505-1510

  Balgkouranidou, Ioanna ^a   Karayiannakis, Anastasios ^a   Matthaios, Dimitrios ^a   Bolanaki, Heleni ^a   Tripsianis, Gregorios ^a   Tentes, Antonios Apostolos ^b   Lianidou, Evi ^c   Chatzaki, Ekaterini ^a   Fiska, Aliki ^a   Lambropoulou, Maria ^a   Kolios, George ^a   Kakolyris, Stylianos ^d  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b General Hospital of Didimotycho   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d University General Hospital of Alexandropolis   (Greece)

Author keywords

cell free DNA; DNA methylation; gastric cancer; prognosis; SOX17

Indexed keywords

DNA; TRANSCRIPTION FACTOR SOX17;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA METHYLATION; FEMALE; GENETIC ASSOCIATION; HUMAN; INCIDENCE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RATING SCALE; SERUM; STOMACH CANCER; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS, GENETIC; SOXF TRANSCRIPTION FACTORS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84882941753     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0320     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005;55:74-108.
2. Hayatt BG, Paull PE, Wassef W. Gastric oncology: An update. Curr Opin Gastroenterol 2009;25:570-8.
3. Callinan PA, Feinberg AP. The emerging science of epigenomics. Hum Mol Genet 2006;15:95-101.
4. Laird PW. The power and promise of DNA methylation markers. Nat Rev Cancer 2003;3:253-66. (Pubitemid 37328861)
5. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002;16:6-21. (Pubitemid 34049633)
6. Kopelovich L, Crowell JA, Fay Jr. The epigenome as a target for cancer chemoprevention. J Natl Cancer Inst 2003;95:1747-57. (Pubitemid 38008897)
7. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349: 2042-54. (Pubitemid 37448928)
8. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28. (Pubitemid 34587077)
9. Dammann R, Yang G, Pfeifer GP. Hypermethylation of the CpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001;61:3105-9. (Pubitemid 32691961)
10. Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, Polyak K, et al. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 2003;107:970-5. (Pubitemid 37429839)
11. Balassiano K, Lima S, Jenab M, Overvad K, Tjonneland A, Boutron-Riault MC. Aberrant DNA methylation of cancer associated genes in gastric cancer in the European Prospective Investigation into cancer and Nutrition (EPIC-EURGAST). Cancer Lett 2011;311:85-95.
12. Fleisher AS, Esteller M, Wang S, Tamura G, Suzuki H, Yin J, et al. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 1999;59:1090-5. (Pubitemid 29135970)
13. Ibanez de Caceres I, Battagli C, Esteller M, Herman JG. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma and peritoneal fluid from ovarian cancer patients. Cancer Res 2004;64:6476-81. (Pubitemid 39297903)
14. Palmisiano WA. Predicting lung cancer by detecting aberrant promote methylation in sputum. Cancer Res 2000;60:5954-8.
15. Goessl C, Muller M, Straub B, Muller K. DNA alterations in body fluids as molecular tumor markers for urological malignancies. Eur Urol 2002;41:668-76. (Pubitemid 35333926)
16. Oishi Y, Watanabe Y, Yoshida Y, Sato Y. Hypermethylation of SOX17 gene is useful as a molecular diagnostic application in early gastric cancer. Tumour Biol 2012;33:383-93.
17. Swarup V, Rajeswari MR. Circulating (cell-free) nucleic acids -A promising non-invasive tool for early detection of several human diseases. FEBS Lett 2007;581:795-9. (Pubitemid 46282711)
18. Mori T, OaDay SJ, Umetani N. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol 2005;23:9351-8.
19. Goebel G, Zitt M, Muller HM. Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias. Dis Markers 2005;21:105-20. (Pubitemid 41566728)
20. Fu DY, Wang ZM, Chen L, Wang BL, Shen ZZ, Huang W, et al. SOX17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer. Breast Cancer Res Tr 2010;119:601-12.
21. Sohn J, Natale J, Chew LJ, Belachew S, Cheng Y, Aguirre A, et al. Identification of SOX17 as a transcription factor that regulates oligodendrocyte development. J Neurosci 2006;26:9722-35. (Pubitemid 44427711)
22. Matsui T, Kanai-Azuma M, Hara K, Matoba S, Hiramatsu R, Kawakami H, et al. Redundant roles of Sox17 and Sox18 in postnatal angiogenesis in mice. J Cell Sci 2006;119: 3513-26. (Pubitemid 44501857)
23. Park KS, Wells JM, Zorn AM, Wert SE, Whitsett JA. Sox17 influences the differentiation of respiratory epithelial cells. Dev Biol 2006;294:192-202.
24. Sinner D, Kordich JJ, Spence JR, Opoca R, Rankin S, Lin SC, et al. Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol 2007;27:7802-15. (Pubitemid 350086414)
25. Zhang W, Glöckner SC, Guo M, Machida EO, Wang DH, Easwaran H, et al. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res 2008;68:2764-72. (Pubitemid 351556274)
26. Du YC, Oshima H, Oguma K, Kitamura T, Itadani H, Fujimura T, et al. Induction and down regulation of SOX17 and its possible roles during the course of gastrointestinal tumorigenesis. Gastroenterology 2009;137:1346-57.
27. Knudson AG. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-3.
28. Korinek V, Barker N, Moerer P, van Donselaar E, Huls G, Peters PJ, et al. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet 1998;19: 379-83. (Pubitemid 28357912)
29. Van de Wetering M, Sancho E, Verweij C, de Lau W, Oving -catenin/TCF-4 complex imposes a crypt progenitor I, Hurlstone A, et al. The phenotype on colorectal cancer cells. Cell 2002;111:241-50. (Pubitemid 35292444)
30. Clements WM, Wang J, Sarnaik A, Kim OJ, MacDonald J, Fenoglio-Preiser C, et al. Beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res 2002;62:3503-6. (Pubitemid 34651399)
31. Fodde R, Smits R, Clevers H. APC signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 2001;1:55-67. (Pubitemid 33741881)
32. -Catenin signaling in cancer 32. Fodde R, Brabletz T. Wnt/ stemness and malignant behavior. Curr Opin Cell Biol 2007;19: 150-8. (Pubitemid 46386404)